Ohara Pharmaceutical

Executive Summary

Ohara Pharmaceutical is a privately-held Japanese pharmaceutical company with a legacy dating back to 1946, employing 200-500 staff. The company focuses on addressing unmet medical needs through a hybrid portfolio of generic drugs and innovative therapeutics, targeting oncology (especially pediatric cancers), hepatobiliary-pancreatic diseases, and central nervous system disorders. Its technology platforms span small molecules, recombinant proteins, and monoclonal antibodies. Despite being a commercial-stage entity, Ohara maintains a diversified R&D pipeline aimed at high-need areas, with a presence in both domestic and potentially global markets. The company's private status limits financial transparency, but its long history suggests operational stability and potential for strategic partnerships or licensing deals to advance its pipeline.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 data readout for lead oncology candidate (pediatric solid tumors)40% success
• Q4 2026Regulatory approval decision for hepatobiliary-pancreatic generic drug in Japan75% success
• H1 2027Announcement of strategic partnership for CNS drug development30% success